Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Laboratory Corporation of America Holdings    LH


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

LabCorp : Announces Pricing Terms of Its Tender Offer for up to $300,000,000 Principal Amount of Its Outstanding 4.625% Senior Notes Due 2020

share with twitter share with LinkedIn share with facebook
share via e-mail
12/03/2019 | 04:51pm EST

LabCorp® (NYSE: LH) announced today the pricing terms of its previously announced cash tender offer (the Offer) for up to $300,000,000 principal amount (the Tender Cap) of its outstanding $600,000,000 aggregate principal amount of 4.625% Senior Notes due 2020 (the Notes). The terms and conditions of the Offer are described in the Offer to Purchase dated Nov. 18, 2019 (the Offer to Purchase) and remain unchanged.

The total consideration (the Total Consideration) for the Notes is based on the yield to maturity of the applicable U.S. Treasury Security (the Reference Yield) plus a fixed spread, as set forth in the table below. The Reference Yield (as determined pursuant to the Offer to Purchase) was determined at 10:00 a.m. EST today, Dec. 3, 2019, by the dealer managers (identified below).

The following table sets forth certain information regarding the Offer, including the Reference Yield and the Total Consideration:

Title of Security




U.S. Treasury




Fixed Spread

(basis points)



(per $1,000)

4.625% Senior

Notes due 2020


1.50% UST due

Aug 15, 2020


30 bps



The Total Consideration is payable to holders of Notes validly tendered and not validly withdrawn at or prior to 5:00 p.m. EST on Dec. 2, 2019 (the Early Tender Deadline) and accepted for purchase by LabCorp. The Total Consideration includes an early tender premium of $30.00 per $1,000 principal amount of Notes validly tendered and not validly withdrawn by such holders and accepted for purchase by LabCorp (the Early Tender Premium). All payments for Notes purchased in connection with the Early Tender Deadline will also include accrued and unpaid interest on the principal amount of Notes tendered up to, but not including, the Early Settlement Date, which is currently expected to be Dec. 4, 2019.

As announced earlier today, LabCorp will accept all Notes validly tendered and not validly withdrawn on or before the Early Tender Deadline. LabCorp will continue to accept Notes tendered after the Early Tender Deadline up to the Tender Cap. Notes may be subject to proration if the aggregate principal amount of the Notes validly tendered is greater than the Tender Cap. The Offer will expire at 11:59 p.m. EST on Dec. 16, 2019, unless extended or earlier terminated by LabCorp (the Expiration Date). Holders of Notes who validly tender their Notes following the Early Tender Deadline and on or prior to the Expiration Date will receive the “Tender Offer Consideration” per $1,000 principal amount of any such Notes tendered by such holders that are accepted for purchase, which is equal to the Total Consideration minus the Early Tender Premium. Holders of Notes accepted for purchase by LabCorp will also receive accrued interest from the most recent interest payment date for the Notes up to, but not including, the applicable settlement date.

The deadline to validly withdraw tenders has passed. Accordingly, Notes that were already tendered at the Early Tender Deadline may not be withdrawn, except in certain limited circumstances where additional withdrawal rights are required by law.

BofA Securities, US Bancorp, and Wells Fargo Securities are acting as dealer managers for the tender offer. The tender agent and information agent for the tender offer is D.F. King & Co., Inc. Questions regarding the tender offer may be directed to BofA Securities at (980) 387-3907 (collect) or (888) 292-0070 (U.S. toll-free), US Bancorp at (612) 336-7604 (collect) or (877) 558-2607 (U.S. toll-free), and Wells Fargo Securities at (704) 410-4759 (collect) or (866) 309-6316 (U.S. toll-free). Holders who would like additional copies of the offer documents may call the information agent, D.F. King & Co., Inc. at (212) 269-5550 (collect, for banks and brokers) or (888) 625-2588 (toll-free, for all others), or by e-mail at labcorp@dfking.com.

This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell the Notes. The tender offer is being made solely by means of the Offer to Purchase that LabCorp distributed to holders of Notes.

About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory, and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11 billion in 2018. To learn more about LabCorp, visit www.LabCorp.com, and to learn more about Covance Drug Development, visit www.Covance.com. The information contained on these websites is not incorporated by reference herein.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements including but not limited to statements pertaining to the Offer. Each of the forward-looking statements is subject to change based on various important factors. Actual results of the Offer could differ materially from those suggested by these forward-looking statements. LabCorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks, and uncertainties that could affect operating and financial results is included in LabCorp’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in LabCorp’s other filings with the SEC.

© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
01/22LABORATORY OF AMERICA : LabCorp Earns 100 Percent on Human Rights Campaign Found..
01/21LABCORP : Earns 100 Percent on Human Rights Campaign Foundation's Annual Scoreca..
01/15LABORATORY OF AMERICA : LabCorp to Adopt Thermo Fisher Scientific's Ion Torrent ..
01/14LABORATORY OF AMERICA : LabCorp to Adopt Thermo Fisher Scientific's Ion Torrent ..
01/14LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
01/13LABCORP : to Announce Fourth Quarter and Full Year 2019 Financial Results on Feb..
01/13LABCORP : and Covance Launch Extensive Preclinical, Clinical and Post-Approval C..
01/10LABORATORY OF AMERICA : Cautionary Statement Regarding Forward-Looking Statement..
01/06LABORATORY CORP OF AMERICA HOLDINGS : Financial Statements and Exhibits (form 8-..
01/06LABCORP : is Scheduled to Present at the 38th Annual J.P. Morgan Healthcare Conf..
More news
Financials (USD)
Sales 2019 11 529 M
EBIT 2019 1 708 M
Net income 2019 801 M
Debt 2019 6 055 M
Yield 2019 -
P/E ratio 2019 21,3x
P/E ratio 2020 18,4x
EV / Sales2019 2,02x
EV / Sales2020 1,90x
Capitalization 17 234 M
Duration : Period :
Laboratory Corporation of America Holdings Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LABORATORY CORPORATION OF
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 191,61  $
Last Close Price 177,49  $
Spread / Highest target 18,3%
Spread / Average Target 7,96%
Spread / Lowest Target -3,09%
EPS Revisions
Adam H. Schechter President, Chief Executive Officer & Director
David P. King Chairman
Glenn Andrew Eisenberg Chief Financial Officer, Treasurer & Executive VP
Lance V. Berberian Chief Information Officer & Senior Vice President
Stephen M. Anderson Chief Scientific Officer-Covance & Senior VP